Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activations

Intergroup trial MAC.13/NCCTG N063D: ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study (A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer) was centrally activated 10 July 2008.

MA.31: A Randomized, Open-Label, Phase III Study of Taxane-Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer was centrally activated 17 July 2008.